Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2023

14.06.2023 | Retinal Disorders

Influence of lesion location on lesion reactivation after initial treatment in neovascular age-related macular degeneration

verfasst von: Jae Hui Kim, Jong Woo Kim, Chul Gu Kim

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aim to evaluate the factors associated with the incidence of lesion reactivation after initial loading injections in patients with neovascular age-related macular degeneration (AMD).

Methods

This retrospective study included patients diagnosed with treatment-naïve neovascular AMD who received three loading injections of either ranibizumab or aflibercept. After the initial treatment, patients were followed up every 1–2 months during the first year and the follow-up interval was extended to 4 months during the second year. Retreatment was administered on an as-needed basis. The incidence and timing of lesion reactivation at 24 months after diagnosis were identified. In addition, Cox’s proportional hazard model was used to evaluate the association of baseline factors with lesion reactivation. Lesion reactivation was defined re-accumulation of subretinal fluid/intraretinal fluid or the development of subretinal/intraretinal hemorrhage.

Results

A total of 284 patients (173 men and 111 women) were included in the study. The mean age of the patients was 70.5 ± 8.8 years. During the 24-month follow-up period, lesion reactivation was observed in 216 eyes (76.1%) at a mean of 8.2 ± 4.4 months after diagnosis. The incidence of lesion reactivation was 62.5% in extrafoveal macular neovascularization (MNV), 75.0% in juxtafoveal MNV, and 79.5% in subfoveal MNV. The extrafoveal MNV showed significantly lower incidence of lesion reactivation than subfoveal MNV (P = 0.041, hazard ratio = 0.64).

Conclusions

Extrafoveal MNVs showed a lower incidence of lesion reactivation after initial treatment than subfoveal MNVs. This result should be considered when interpreting the results of clinical trials with different eligibility criteria regarding lesion location.
Literatur
1.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMed Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMed
2.
Zurück zum Zitat Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548CrossRefPubMed Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548CrossRefPubMed
3.
Zurück zum Zitat Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72–84CrossRefPubMed Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72–84CrossRefPubMed
4.
Zurück zum Zitat Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729–740CrossRefPubMed Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729–740CrossRefPubMed
6.
Zurück zum Zitat Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, Kotecha A, Lin H, Silverman D, Swaminathan B, Willis JR, Yoon YH, Quezada-Ruiz C (2021) TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci 1:100076CrossRefPubMedPubMedCentral Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, Kotecha A, Lin H, Silverman D, Swaminathan B, Willis JR, Yoon YH, Quezada-Ruiz C (2021) TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci 1:100076CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : a randomized controlled trial. Adv Ther 37:1173–1187CrossRefPubMedPubMedCentral Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : a randomized controlled trial. Adv Ther 37:1173–1187CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S (2021) Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina 41:1911–1920CrossRefPubMedPubMedCentral Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S (2021) Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina 41:1911–1920CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Brown GC, Brown MM, Rapuano S, Boyer D (2020) Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration. Am J Ophthalmol 218:225–241CrossRefPubMed Brown GC, Brown MM, Rapuano S, Boyer D (2020) Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration. Am J Ophthalmol 218:225–241CrossRefPubMed
10.
Zurück zum Zitat Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R (2015) Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 160(725-731):e721 Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R (2015) Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 160(725-731):e721
11.
Zurück zum Zitat Iglicki M, González DP, Loewenstein A, Zur D (2021) Longer-acting treatments for neovascular age-related macular degeneration-present and future. Eye (Lond) 35:1111–1116CrossRefPubMed Iglicki M, González DP, Loewenstein A, Zur D (2021) Longer-acting treatments for neovascular age-related macular degeneration-present and future. Eye (Lond) 35:1111–1116CrossRefPubMed
12.
Zurück zum Zitat Meer EA, Oh DH, Brodie FL (2022) Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons. Clin Ophthalmol 16:4273–4279CrossRefPubMedPubMedCentral Meer EA, Oh DH, Brodie FL (2022) Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons. Clin Ophthalmol 16:4273–4279CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303–2310CrossRefPubMed Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303–2310CrossRefPubMed
14.
Zurück zum Zitat Kim JH, Kim JW, Kim CG (2021) Five-year reactivation after ranibizumab or aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 37:525–533CrossRefPubMed Kim JH, Kim JW, Kim CG (2021) Five-year reactivation after ranibizumab or aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 37:525–533CrossRefPubMed
15.
Zurück zum Zitat Kim JH, Kim JW, Kim CG (2022) Difference in lesion reactivation between pure type 2 and mixed type 1 and 2 macular neovascularization and its influence on long-term treatment outcomes. Semin Ophthalmol:1–7 Kim JH, Kim JW, Kim CG (2022) Difference in lesion reactivation between pure type 2 and mixed type 1 and 2 macular neovascularization and its influence on long-term treatment outcomes. Semin Ophthalmol:1–7
16.
Zurück zum Zitat Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8CrossRefPubMed Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8CrossRefPubMed
17.
Zurück zum Zitat Parodi MB, Iacono P, La Spina C, Iuliano L, Lo Giudice G, Introini U, Bandello F (2014) Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration. Retina 34:2167–2170CrossRefPubMed Parodi MB, Iacono P, La Spina C, Iuliano L, Lo Giudice G, Introini U, Bandello F (2014) Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration. Retina 34:2167–2170CrossRefPubMed
18.
Zurück zum Zitat Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U (2014) Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration. Retina 34:860–867CrossRefPubMed Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U (2014) Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration. Retina 34:860–867CrossRefPubMed
19.
Zurück zum Zitat Ladas ID, Chatziralli IP, Kotsolis AI, Douvali M, Georgalas I, Theodossiadis PG, Rouvas AA (2012) Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration. Ophthalmologica 228:93–101CrossRefPubMed Ladas ID, Chatziralli IP, Kotsolis AI, Douvali M, Georgalas I, Theodossiadis PG, Rouvas AA (2012) Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration. Ophthalmologica 228:93–101CrossRefPubMed
20.
Zurück zum Zitat Ying GS, Maguire MG, Pan W, Grunwald JE, Daniel E, Jaffe GJ, Toth CA, Hagstrom SA, Martin DF (2018) Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials. Ophthalmol Retina 2:525–530CrossRefPubMedPubMedCentral Ying GS, Maguire MG, Pan W, Grunwald JE, Daniel E, Jaffe GJ, Toth CA, Hagstrom SA, Martin DF (2018) Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials. Ophthalmol Retina 2:525–530CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Augsburger M, Sarra GM, Imesch P (2019) Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol 257:1889–1895CrossRefPubMed Augsburger M, Sarra GM, Imesch P (2019) Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol 257:1889–1895CrossRefPubMed
22.
Zurück zum Zitat Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2016) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 100:914–917CrossRefPubMed Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2016) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 100:914–917CrossRefPubMed
23.
Zurück zum Zitat Chaikitmongkol V, Sagong M, Lai TYY, Tan GSW, Ngah NF, Ohji M, Mitchell P, Yang CH, Ruamviboonsuk P, Wong I, Sakamoto T, Rajendran A, Chen Y, Lam DSC, Lai CC, Wong TY, Cheung CMG, Chang A, Koh A (2021) Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific vitreo-retina society. Asia Pac J Ophthalmol (Phila) 10:507–518CrossRefPubMed Chaikitmongkol V, Sagong M, Lai TYY, Tan GSW, Ngah NF, Ohji M, Mitchell P, Yang CH, Ruamviboonsuk P, Wong I, Sakamoto T, Rajendran A, Chen Y, Lam DSC, Lai CC, Wong TY, Cheung CMG, Chang A, Koh A (2021) Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific vitreo-retina society. Asia Pac J Ophthalmol (Phila) 10:507–518CrossRefPubMed
24.
Zurück zum Zitat Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226CrossRefPubMed Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226CrossRefPubMed
25.
Zurück zum Zitat Kvannli L, Krohn J (2017) Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration. Acta Ophthalmol 95:678–682CrossRefPubMed Kvannli L, Krohn J (2017) Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration. Acta Ophthalmol 95:678–682CrossRefPubMed
26.
Zurück zum Zitat Hatz K, Prunte C (2016) Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 100:1341–1345CrossRefPubMed Hatz K, Prunte C (2016) Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 100:1341–1345CrossRefPubMed
27.
Zurück zum Zitat Kim JH, Kim JW, Kim CG (2022) Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization. Sci Rep 12:22546CrossRefPubMedPubMedCentral Kim JH, Kim JW, Kim CG (2022) Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization. Sci Rep 12:22546CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, Munk MR, McAllister IL (2020) Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology 127:198–210CrossRefPubMed Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, Munk MR, McAllister IL (2020) Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology 127:198–210CrossRefPubMed
29.
Zurück zum Zitat Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye. Graefes Arch Clin Exp Ophthalmol 257:891–898CrossRefPubMed Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye. Graefes Arch Clin Exp Ophthalmol 257:891–898CrossRefPubMed
30.
Zurück zum Zitat Kiss S, Campbell J, Almony A, Shih V, Serbin M, LaPrise A, Wykoff CC (2020) Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records. Ophthalmology 127:1179–1188CrossRefPubMed Kiss S, Campbell J, Almony A, Shih V, Serbin M, LaPrise A, Wykoff CC (2020) Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records. Ophthalmology 127:1179–1188CrossRefPubMed
31.
Zurück zum Zitat Kim YH, Lee B, Kang E, Oh J (2021) Clustering of eyes with age-related macular degeneration or pachychoroid spectrum diseases based on choroidal thickness profile. Sci Rep 11:4999CrossRefPubMedPubMedCentral Kim YH, Lee B, Kang E, Oh J (2021) Clustering of eyes with age-related macular degeneration or pachychoroid spectrum diseases based on choroidal thickness profile. Sci Rep 11:4999CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Gunter R, Szeto E, Jeong SH, Suh S, Waters AJ (2020) Cigarette smoking in South Korea: a narrative review. Korean J Fam Med 41:3–13CrossRefPubMed Gunter R, Szeto E, Jeong SH, Suh S, Waters AJ (2020) Cigarette smoking in South Korea: a narrative review. Korean J Fam Med 41:3–13CrossRefPubMed
33.
Zurück zum Zitat Shin HT, Yoon BW, Seo JH (2021) Comparison of risk allele frequencies of single nucleotide polymorphisms associated with age-related macular degeneration in different ethnic groups. BMC Ophthalmol 21:97CrossRefPubMedPubMedCentral Shin HT, Yoon BW, Seo JH (2021) Comparison of risk allele frequencies of single nucleotide polymorphisms associated with age-related macular degeneration in different ethnic groups. BMC Ophthalmol 21:97CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Shah AM, Bressler NM, Jampol LM (2011) Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol 152:332–339.e331CrossRefPubMed Shah AM, Bressler NM, Jampol LM (2011) Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol 152:332–339.e331CrossRefPubMed
35.
Zurück zum Zitat Macular Photocoagulation Study Group (1991) Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 109:1109–1114 Macular Photocoagulation Study Group (1991) Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 109:1109–1114
36.
Zurück zum Zitat Kim JH, Kim JW, Kim CG (2021) Eyes that do not meet the eligibility criteria of clinical trials on age-related macular degeneration: proportion of the real-world patient population and reasons for exclusion. J Ophthalmol 2021:6635467CrossRefPubMedPubMedCentral Kim JH, Kim JW, Kim CG (2021) Eyes that do not meet the eligibility criteria of clinical trials on age-related macular degeneration: proportion of the real-world patient population and reasons for exclusion. J Ophthalmol 2021:6635467CrossRefPubMedPubMedCentral
Metadaten
Titel
Influence of lesion location on lesion reactivation after initial treatment in neovascular age-related macular degeneration
verfasst von
Jae Hui Kim
Jong Woo Kim
Chul Gu Kim
Publikationsdatum
14.06.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2023
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-023-06144-8

Weitere Artikel der Ausgabe 11/2023

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2023 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.